search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA MedPage Today

Show articles from

8-Week HCV Combo Falls Short

Eight weeks of hepatitis C (HCV) treatment with a novel three-drug combination was not as good as an older combination of two drugs delivered for 12 weeks, a researcher reported here.

HBV Immunotherapy Safe But Efficacy Lacking

Use of of an investigational immunotherapy called GS-4774 in combination with tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients was safe and well tolerated in a phase II study, investigators reported here.

HCV Combo Tx Shows Wide Efficacy

Ninety-nine percent of hepatitis C patients with five genotypes achieve cure

HCV Patients With Cirrhosis Respond Well to Combo Tx

Sofosbuvir-velpatasvir appears optimal when paired with ribavirin

HCV Treatment May Benefit Injection-Drug Users

High compliance rates, sustained virologic response with investigational combination

HIV/HCV Outcomes Good in Real World

In patients infected with both HIV and hepatitis C (HCV), direct-acting antiviral agents produced high rates of 12-week HCV viral eradication, particularly in patients without decompensated cirrhosis, a Spanish investigator reported here.

Lasting Effects for Obeticholic Acid in Primary Biliary Cirrhosis

Extension studies suggest investigational drug has efficacy up to 5 years

Liver Cancer Rare After HCV Therapy

BOSTON -- For patients with advanced liver disease owing to hepatitis C (HCV), treatment with direct-acting antiviral agents did not increase the risk of hepatocellular carcinoma, a researcher said here.

Novel HCV Drug Combo Shines in CKD Patients

An investigational combination of antiviral agents was almost universally successful in curing hepatitis C (HCV) patients with severe kidney disease, a researcher said here.

Peg-Interferon Effective in Kids with Chronic HBV

Pegylated interferon alfa-2a is effective in children and teens with chronic hepatitis B (HBV), an investigator reported here, and is also well tolerated.

Specialty Care No Longer Needed for HCV

BOSTON -- In the era of direct-acting agents against hepatitis C (HCV), the treatment of many patients can be effectively referred to nonspecialist care without loss of efficacy, a researcher reported here.

VA HCV Cures Skyrocket

In the past 16 years, Veterans' Administration doctors have cured more than 57,000 people with hepatitis C (HCV) -- about half of them in 2015, a researcher said here.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site